SCHEMBL6476247

SCHEMBL6476247

O=C(O)C(O)C1CCCc2ccccc21

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.49
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
ALDH1A1 P00352 3/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
RAB9A P51151 1/20 0.44
TSHR P16473 2/20 0.43
BLM P54132 1/20 0.43
EPHX1 P07099 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
CAMK2A Q9UQM7 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
XBP1 P17861 1/20 0.43
IDO1 P14902 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5285710 0.83 HTT (0.48) HTTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL30644032 0.83 HTT (0.48) HTTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL8809100 0.82 TSHR (0.53) HTTMEN1KMT2AALDH1A1TSHR
SCHEMBL21400761 0.81 IDO1 (0.49) HTTMEN1KMT2AALDH1A1BLM
SCHEMBL10389080 0.80 KDM4E (0.48) ALDH1A1SMN1; SMN2RAB9ATSHR
SCHEMBL2993631 0.80 HTT (0.46) HTTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL3397663 0.79 HTT (0.48) HTTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL8802816 0.79 TSHR (0.50) HTTMEN1KMT2AALDH1A1TSHR
SCHEMBL9500102 0.78 IDO1 (0.50) HTTMEN1KMT2AALDH1A1BLM
Hydrogen Peroxide SCHEMBL9456544 0.78 IDO1 (0.46) HTTMEN1KMT2AALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6900319-B2 Thrombin inhibitors ABBOTT GMBH & CO. KG (DE) 2005-05-31 US disclosed
US-20020169318-A1 Novel thrombin inhibitors ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2002-11-14 US disclosed
US-6444817-B1 ANTICOAGULANTS ABBOTT LABORATORIES 2002-09-03 US disclosed
US-6030972-A 2- OR 5-AMINOMETHYL,2- OR 5-CYANOPYRIMIDINES AS INTERMEDIATES OF ANTICOAGULANTS IN EXTRACORPOREAL CIRCULATION (HEART-LUNG MACHINE, HEMODIALYSIS) BASF AKTIENGESELLSCHAFT (DE) 2000-02-29 US disclosed
WO-1996025426-A1 NOVEL DIPEPTIDE AMIDINES AS THROMBIN INHIBITORS BASF AKTIENGESELLSCHAFT (DE) 1996-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169318-A1 Novel thrombin inhibitors TFPI, SERPINC1, F11 HTT 4179/4885MEN1 670/4885KMT2A 3199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.